Well in many companies - they reduce staff from a dept when focus is shifted. (pfizer reduce some 300 people from CNS division when they decided to exit ALZ and Parkinson research.
Co told that they stopped K trial - no further activity till K oral formulation is done - not known when.
So more logical conclusion with common people is - no focus on K, Menon who was mainly for K has reduced responsibility so his salary is reduced
Other staff reduction - co did not have that high staff if one considers 3 products - so eliminating staff also tells that focus from some product activity - not more activity - one such activity is trials - no upcoming trials of any sort as no enough money - so staff elimination
Remembering the good old days of mid February, 2018.
"Brilacidin OM could be partnered any day or the whole franchise for that matter.... "
"Any day now ------ Prurisol data will be released."
It appears none of we longs have been accurate with predictions. Nor does it appear management is too concerned about shareholder value. To bad Boston is viewed as a hick town by some. There's big money players always looking for a good return.